Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Caner and inflammatory diseases focused Tiziana Life Sciences said it planned to demerge its StemPrintER genomics-based personalised medicine business into a separate company.
The company said recent positive trial results on the prediction of disease recurrence in breast cancer patients backed the viability of StemPrintER as having the potential to be a standalone business.
On its own, StemPrintER could secure separate financial resources and sharpen its focus onto the personalised medicine market.
The separation would be done via a capital reduction and was subject to shareholder approval.
At 9:11am: (LON:TILS) Tiziana Life Sciences Plc share price was +8p at 93p